Patents by Inventor Elfatih Elzein

Elfatih Elzein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cannabinoid receptor type 2 (CB2) modulators and uses thereof
    Patent number: 11957689
    Abstract: Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).
    Type: Grant
    Filed: October 5, 2022
    Date of Patent: April 16, 2024
    Assignee: Teon Therapeutics, Inc.
    Inventors: Elfatih Elzein, Jiwen Liu
  • COMBINATION THERAPY WITH ADENOSINE RECEPTOR ANTAGONISTS
    Publication number: 20240041889
    Abstract: Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor in combination with immune checkpoint inhibitors in mammals with cancer.
    Type: Application
    Filed: August 6, 2021
    Publication date: February 8, 2024
    Inventors: PEIDONG FAN, LINA YAO, JIWEN LIU, ELFATIH ELZEIN
  • CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF
    Publication number: 20230143502
    Abstract: Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).
    Type: Application
    Filed: October 5, 2022
    Publication date: May 11, 2023
    Inventors: Elfatih Elzein, Jiwen Liu
  • Cannabinoid receptor type 2 (CB2) modulators and uses thereof
    Patent number: 11564928
    Abstract: Disclosed herein are compounds, compositions, and methods for modulating the Cannabinoid receptor 2 (CB2) with the compounds and compositions disclosed herein. Also described are methods of treating diseases or conditions that are mediated by the action of Cannabinoid receptor 2 (CB2) or that we benefit from modulating the Cannabinoid receptor 2 (CB2).
    Type: Grant
    Filed: March 10, 2022
    Date of Patent: January 31, 2023
    Assignee: Teon Therapeutics, Inc.
    Inventors: Elfatih Elzein, Jiwen Liu
  • ADENOSINE A2A RECEPTOR ANTAGONISTS
    Publication number: 20230024108
    Abstract: Disclosed herein are compounds, compositions, and methods for modulating the A2A adenosine receptor with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the A2A adenosine receptor, such as cancer, with A2A adenosine receptor antagonists.
    Type: Application
    Filed: July 15, 2020
    Publication date: January 26, 2023
    Inventors: Elfatih Elzein, Jiwen Liu
  • ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20220056033
    Abstract: Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor.
    Type: Application
    Filed: August 2, 2021
    Publication date: February 24, 2022
    Inventors: Jiwen Liu, Elfatih Elzein
  • Therapeutic heterocyclic compounds
    Patent number: 11229638
    Abstract: Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: January 25, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna M. Elbel, Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q. Parkhill, Thao Perry
  • Adenosine receptor antagonists and uses thereof
    Patent number: 11124515
    Abstract: Disclosed herein are compounds of Formula (III), compositions and formulations thereof, and methods for modulating the A22B adenosine receptor for treatment of A2B adenosine receptor mediated diseases or conditions.
    Type: Grant
    Filed: February 2, 2021
    Date of Patent: September 21, 2021
    Assignee: Teon Therapeutics, Inc.
    Inventors: Jiwen Liu, Elfatih Elzein
  • Therapeutic heterocyclic compounds
    Patent number: 11098027
    Abstract: Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: August 24, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Elfatih Elzein, Xiaofen Li
  • Therapeutic heterocyclic compounds
    Patent number: 11040033
    Abstract: Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: June 22, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna M. Elbel, Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q. Parkhill, Thao Perry
  • ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20210163483
    Abstract: Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor.
    Type: Application
    Filed: February 2, 2021
    Publication date: June 3, 2021
    Inventors: Jiwen Liu, Elfatih Elzein
  • ADENOSINE RECEPTOR ANTAGONISTS AND USES THEREOF
    Publication number: 20210040097
    Abstract: Disclosed herein are compounds, compositions, formulations, and methods for modulating the A2B adenosine receptor.
    Type: Application
    Filed: March 5, 2019
    Publication date: February 11, 2021
    Inventors: Jiwen LIU, Elfatih ELZEIN
  • THERAPEUTIC HETEROCYCLIC COMPOUNDS
    Publication number: 20200316035
    Abstract: Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:
    Type: Application
    Filed: August 20, 2018
    Publication date: October 8, 2020
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna M. Elbel, Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q. Parkhill, Thao Perry
  • THERAPEUTIC HETEROCYCLIC COMPOUNDS
    Publication number: 20200031801
    Abstract: Compounds having the following Formula (I), or a pharmaceutically acceptable salt thereof, and methods of their use and preparation are disclosed:
    Type: Application
    Filed: July 3, 2019
    Publication date: January 30, 2020
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Elfatih Elzein, Xiaofen Li
  • Therapeutic heterocyclic compounds
    Publication number: 20190192504
    Abstract: Compounds having the following Formula I and/or Formula II and methods of their use and preparation are disclosed:
    Type: Application
    Filed: August 20, 2018
    Publication date: June 27, 2019
    Inventors: Mark J. Bartlett, Britton Kenneth Corkey, Jennifer Leigh Cosman, Kristyna M, Elbel, Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q Parkhill, Thao Perry
  • Fused heterocyclic compounds as CaM kinase inhibitors
    Patent number: 10100058
    Abstract: The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R1, R2, R3, R4, R5, R6, R9 and R10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: October 16, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q. Parkhill, Thao Perry, Scott Preston Simonovich, Jeff Zablocki, Christopher Allen Ziebenhaus
  • FUSED HETEROCYCLIC COMPOUNDS AS CAM KINASE INHIBITORS
    Publication number: 20180148457
    Abstract: The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general structure of the compounds is given by Formula I: wherein R1, R2, R3, R4, R5, R6, R9 and R10 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Application
    Filed: November 29, 2017
    Publication date: May 31, 2018
    Inventors: Elfatih Elzein, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Eric Q. Parkhill, Thao Perry, Scott Preston Simonovich, Jeff Zablocki, Christopher Allen Ziebenhaus
  • Fused heterocyclic compounds as ion channel modulators
    Patent number: 9695192
    Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Y, Z, n, R1 and R3 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: July 4, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Kenneth Corkey, Elfatih Elzein, Robert H. Jiang, Rao V. Kalla, Dmitry Koltun, Xiaofen Li, Ruben Martinez, Eric Q. Parkhill, Thao Perry, Jeff Zablocki, Chandrasekar Venkataramani, Michael Graupe, Juan Guerrero
  • Fused heterocyclic compounds as ion channel modulators
    Patent number: 9682998
    Abstract: The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R1, X1, X2, Y and R2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    Type: Grant
    Filed: June 21, 2016
    Date of Patent: June 20, 2017
    Assignee: Gilead Sciences, Inc.
    Inventors: Britton Kenneth Corkey, Elfatih Elzein, Michael Graupe, Juan Guerrero, Robert H. Jiang, Rao V. Kalla, Tetsuya Kobayashi, Dmitry Koltun, Xiaofen Li, Ruben Martinez, Gregory Notte, Eric Q. Parkhill, Thao Perry, Chandrasekar Venkataramani, Jeff Zablocki
  • Process for preparing an A2A-adenosine receptor agonist and its polymorphs
    Patent number: RE47301
    Abstract: Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
    Type: Grant
    Filed: July 19, 2017
    Date of Patent: March 19, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Jeff Zablocki, Elfatih Elzein, Robert Seemayer, Travis Lemons